Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer
Michaela Onstad, Robert L. Coleman, Shannon N. Westin
Topics & Concepts
OlaparibOvarian cancerMedicinePARP inhibitorOncologyPopulationBiomarkerVeliparibInternal medicineCancerPoly ADP ribose polymeraseHazard ratioBRCA mutationPharmacologyBiologyPolymeraseGeneticsConfidence intervalGeneEnvironmental healthPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentToxin Mechanisms and Immunotoxins